Navigation Links
Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma
Date:3/2/2010

For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments. National Jewish clinician-scientists Stanley Szefler, Joseph Spahn, Ronina Covar Gary Larsen and Lynn Taussig, and colleagues in the NIH-funded Childhood Asthma Research and Education Network published their findings March 2, 2010, online in the New England Journal of Medicine.

"This study gives physicians confidence in using long-acting beta-agonists if a patient is not responding to steroid treatment alone," said said Dr. Szefler, Professor of Pediatrics and Pharmacology at National Jewish Health. "It also shows that children respond quite differently to different step-up therapies. Doctors need to monitor their patients closely and consider switching to a higher dose of inhaled corticosteroids or a leukotriene receptor antagonist if the long-acting beta agonist does not improve asthma control."

Approximately 7 million children in the United States have asthma. The prevalence has more than doubled in the past several decades. Asthma in the United States accounts for 500,000 hospitalizations, 10.5 million physician-office visits, and 3,500 deaths as well as millions of missed school days.

Almost all the children responded differently to the three step-up therapies. About 45 percent of the children responded best to the long-acting beta agonist salmeterol, 28 percent responded best to the leukotriene receptor antagonist montelukast, and 27 responded best to doubling the dose of the inhaled corticoteroid fluticasone.

The study, called Best Add on Therapy Giving Effective Responses (BADGER), compared the effectiveness of three different step-up treatments in 182 children ages 6 to 18. Participants had mild to moderate persistent asthma that was not controlled on low-dose inhaled corticosteroids.

Researchers also found that certain patient characteristics indentified which step-up treatment would be most effective. African-Americans were equally likely to respond best to LABA step-up or corticosteroid step-up, but not the montelukast. The addition of LABA step-up therapy was most likely to give the best response to white patients, with inhaled corticosteroid step-up the least favorable. The long-acting beta agonist especially likely to help asthma patients who did not have eczema.


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Medical and Research Center
Source:Eurekalert

Related medicine news :

1. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. Studies Ignite Hope for Long-Acting Allergy Vaccines
3. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
4. Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
5. US Back Pain Market Approaches $23 Billion in 2018 - Anticipated Long-Acting, Abuse-Resistant Opioids Drive Value
6. Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven
7. Researchers Create Long-Acting Local Anesthetic
8. Olanzapine Long-Acting Injection (LAI) Efficacy and Safety Data Presented at American Psychiatric Association Annual Meeting
9. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
10. New tool to improve patient understanding of long-acting injectable antipsychotic therapies (LAT) unveiled in April issue of Psychiatry 2009
11. Long-Acting Insulin Works Best for Many Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: